Panitumumab (pmab) plus AMG 102 in patients (pts) with wild-type KRAS metastatic colorectal cancer (mCRC): Updated safety results

被引：2

作者：

Eng, C.

Tabernero, J.

Nowara, E.

Swieboda-Sadlej, A.

Tebbutt, N. C.

Mitchell, E. P.

Davidenko, I.

Chen, L.

Smethurst, D.

Van Cutsem, E.

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Vall dHebron Univ Hosp, Barcelona, Spain

[3] Ctr Onkol Inst Merii Sk, Gliwice, Poland

[4] Warszawski Uniwersytet Med, Warsaw, Poland

[5] Austin Hosp, Heidelberg, Vic 3084, Australia

[6] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA

[7] Krasnodar City Oncol Ctr, Krasnodar, Russia

[8] Amgen Inc, Thousand Oaks, CA USA

[9] Amgen Inc, Uxbridge, Middx, England

[10] Univ Hosp Gasthuisberg, Dept Digest Oncol, B-3000 Louvain, Belgium

来源：

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.e14083

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e14083

引用

页数：1